FEATURES OF PRIMARY AND ADAPTIVE IMMUNOTHERAPY RESISTANCE IN MICROSATELLITE INSTABLE CANCERS

FEATURES OF PRIMARY AND ADAPTIVE IMMUNOTHERAPY RESISTANCE IN MICROSATELLITE INSTABLE CANCERS

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to examine genetic changes in your tumor that may contribute to resistance to immunotherapy. With this information, we hope to be able to identify new treatment methods as well as improve our ability to identify patients more likely to respond to immunotherapy.

Who Can Participate?

Eligibility

Adults ages 18 and older who:
  • Are diagnosed with stage III or IV endometrial, prostate, hepatobiliary, pancreatic, and gastrointestinal cancers with certain tumor mutations
  • Do not have prostate tumors with small cell component
  • Are not pregnant or breastfeeding

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join this study, you will:
  • Go through a screening period to see if you're eligible for the study
  • Start participating before, during, or after treatment with standard of care immunotherapy for your cancer
If you're eligible to join, you will be monitored until you complete your immunotherapy treatment and the final blood and/or tissue samples are collected. During this monitoring period, we will collect the following from you:
  • Blood samples
  • Stool samples
  • Tumor tissue samples

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

FEATURES OF PRIMARY AND ADAPTIVE IMMUNOTHERAPY RESISTANCE IN MICROSATELLITE INSTABLE CANCERS (PAIR-MSI)

Principal Investigator

Nicholas
DeVito

Protocol Number

PRO00105726

NCT ID

NA

Phase

N/A

Enrollment Status

Open to Enrollment
ClinicalTrials.gov